FLGT vs NEOG: fair value comparison
Fulgent Genetics, Inc. and Neogen Corporation · Updated 2026-10-19
FLGT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, FLGT currently ranks higher by quality score.
| FLGT | NEOG | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $19.81 | $11.81 |
| 12-month range | $13.79–$30.85 | $5.41–$13.98 |
| Rank by discount to fair value | — | #103 of 108 Healthcare |
| Rank by quality score | #145 of 301 Healthcare | #146 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: FLGT fair value analysis · NEOG fair value analysis